Intraductal Carcinoma of the Prostate Gland: Recent Advances.
10.3349/ymj.2016.57.5.1054
- Author:
Mukul K DIVATIA
1
;
Jae Y RO
Author Information
1. Department of Pathology and Genomic Medicine, Houston Methodist Hospital, Weill Medical College of Cornell University, Houston, TX, USA. jaero@houstonmethodist.org
- Publication Type:Review
- Keywords:
Intraductal carcinoma of prostate;
high-grade prostatic intraepithelial neoplasia;
prostatic ductal adenocarcinoma
- MeSH:
Carcinoma, Acinar Cell/chemistry/*diagnosis/pathology;
Carcinoma, Ductal/chemistry/*diagnosis/pathology;
Carcinoma, Transitional Cell/chemistry/*diagnosis/pathology;
Diagnosis, Differential;
Humans;
Male;
Neoplasm Grading;
Prostatic Intraepithelial Neoplasia/chemistry/*diagnosis/pathology;
Prostatic Neoplasms/chemically induced/*diagnosis/*pathology;
Tumor Burden
- From:Yonsei Medical Journal
2016;57(5):1054-1062
- CountryRepublic of Korea
- Language:English
-
Abstract:
Intraductal carcinoma of the prostate (IDC-P) is characterized by prostatic carcinoma involving ducts and/or acini. The presence of IDC-P is usually associated with a high-grade Gleason score, large tumor volume, and adverse prognostic parameters, including extraprostatic extension and seminal vesicle invasion. When present, IDC-P is associated with worse outcomes, regardless of treatment status. IDC-P is included in a broader diagnostic category of atypical cribriform lesions of the prostate gland. This category of lesions also includes high-grade prostatic intraepithelial neoplasia (HGPIN), urothelial carcinoma involving prostatic ducts or acini, and prostatic ductal adenocarcinoma, amongst other intraductal proliferations. Differentiating between these entities is important as they have differing therapeutic and prognostic implications for patients, although differential diagnosis thereof is not always straightforward. The present review discusses IDC-P in regards to its morphological characteristics, molecular features, and clinical outcomes. Given the current state of knowledge, the presence of IDC-P should be evaluated and documented correctly in both radical prostatectomy and needle biopsy specimens, and the clinical implications thereof should be taken into consideration during treatment and follow up.
